Elevated Aromatase (CYP19A1) Expression Is Associated with a Poor Survival of Patients with Estrogen Receptor Positive Breast Cancer.

Abstract:

:Genetic variants in CYP19A1, the gene encoding aromatase, have been reported to be associated with circulating estrogen concentrations, a key risk factor for breast cancer. The mechanism underlying this association is still unclear; it has been suggested that some of these variants may alter the expression and/or activity of aromatase. Here we analyzed the expression of intra-tumoral CYP19A1 messenger RNA (mRNA) and the genotypes of rs10046, a well-characterized single nucleotide polymorphism in CYP19A1, in 138 breast cancer patients and 15 breast cancer cell lines. The genotype TT was detected in 36 patients and six cell lines, genotype CT in 55 patients and five cell lines, and genotype CC in 28 patients and four cell lines. We found no evidence for a significant association of CYP19A1 levels with rs10046 genotypes, although expression tended to be higher in tumors and cell lines with the homozygous risk genotype TT. We also found no evidence for a significant association of rs10046 genotypes with breast cancer prognosis. In contrast, high CYP19A1 expression was highly significantly associated with a poor overall, disease-free, and metastasis-free survival in estrogen receptor-positive but not negative breast cancer patients. Moreover, CYP19A1 mRNA was significantly elevated in postmenopausal patients and in patients older than 50 years, and a trend towards a positive correlation with ER status and ESR1 mRNA expression was observed. These findings highlight the key role of aromatase in estrogen receptor-positive breast cancer biology.

journal_name

Horm Cancer

journal_title

Hormones & cancer

authors

Friesenhengst A,Pribitzer-Winner T,Miedl H,Pröstling K,Schreiber M

doi

10.1007/s12672-017-0317-2

subject

Has Abstract

pub_date

2018-04-01 00:00:00

pages

128-138

issue

2

eissn

1868-8497

issn

1868-8500

pii

10.1007/s12672-017-0317-2

journal_volume

9

pub_type

杂志文章
  • Risk Analysis of Prostate Cancer Treatments in Promoting Metabolic Syndrome Development and the Influence of Increased Metabolic Syndrome on Prostate Cancer Therapeutic Outcome.

    abstract::In clinical practice, few prostate cancer (PCa) patients are associated with metabolic syndrome (MetS), while few others acquire MetS during treatment. Whether the treatment of PCa increases the occurrence of MetS remains to be confirmed. This study reviewed the changes in MetS patients before and after PCa treatment ...

    journal_title:Hormones & cancer

    pub_type: 杂志文章

    doi:10.1007/s12672-018-0335-8

    authors: Chen Z,Deng J,Yan Y,Li M,Chen C,Chen C,Zhao S,Song T,Liu T,Wen X,Yao Y

    更新日期:2018-08-01 00:00:00

  • Prostate cancer stem cells: do they have a basal or luminal phenotype?

    abstract::The prostate is a luminal secretory tissue whose function is regulated by male sex hormones. Castration produces involution of the prostate to a reversible basal state, and as the majority of prostate cancers also have a luminal phenotype, drug-induced castration is a front line therapy. It has therefore been assumed ...

    journal_title:Hormones & cancer

    pub_type: 杂志文章

    doi:10.1007/s12672-010-0058-y

    authors: Maitland NJ,Frame FM,Polson ES,Lewis JL,Collins AT

    更新日期:2011-02-01 00:00:00

  • 5th International ACC Symposium: Future and Current Therapeutic Trials in Adrenocortical Carcinoma.

    abstract::Adrenocortical carcinoma (ACC) is a rare and complex disease associated with a high mortality rate. Despite intensive translational and clinical research, prognosis remains poor. Over the past decade, a significant effort has been made to develop multinational, collaborative studies to better understand the pathogenes...

    journal_title:Hormones & cancer

    pub_type: 杂志文章,评审

    doi:10.1007/s12672-015-0241-2

    authors: Hoff AO,Berruti A

    更新日期:2016-02-01 00:00:00

  • Elevated APOBEC3B correlates with poor outcomes for estrogen-receptor-positive breast cancers.

    abstract::Recent observations connected DNA cytosine deaminase APOBEC3B to the genetic evolution of breast cancer. We addressed whether APOBEC3B is associated with breast cancer clinical outcomes. APOBEC3B messenger RNA (mRNA) levels were related in 1,491 primary breast cancers to disease-free (DFS), metastasis-free (MFS), and ...

    journal_title:Hormones & cancer

    pub_type: 杂志文章

    doi:10.1007/s12672-014-0196-8

    authors: Sieuwerts AM,Willis S,Burns MB,Look MP,Meijer-Van Gelder ME,Schlicker A,Heideman MR,Jacobs H,Wessels L,Leyland-Jones B,Gray KP,Foekens JA,Harris RS,Martens JW

    更新日期:2014-12-01 00:00:00

  • Influence of Cancer-Associated Endometrial Stromal Cells on Hormone-Driven Endometrial Tumor Growth.

    abstract::Cancer-associated fibroblasts have been shown to inhibit or stimulate tumor growth depending on stage, grade, and tumor type. It remains unclear, however, the effect of endometrial-cancer-associated fibroblasts on hormone-driven responses in endometrial cancer. In this study, we investigated the effect of normal and c...

    journal_title:Hormones & cancer

    pub_type: 杂志文章

    doi:10.1007/s12672-015-0223-4

    authors: Pineda MJ,Lu Z,Cao D,Kim JJ

    更新日期:2015-08-01 00:00:00

  • The Complex Biology of the Aryl Hydrocarbon Receptor and Its Role in the Pituitary Gland.

    abstract::The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor best known for its ability to mediate the effects of environmental toxins such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD or dioxin), polycyclic aromatic hydrocarbons (PAHs), benzene, and polychlorinated biphenyls (PCBs) through the initi...

    journal_title:Hormones & cancer

    pub_type: 杂志文章,评审

    doi:10.1007/s12672-017-0300-y

    authors: Formosa R,Vassallo J

    更新日期:2017-08-01 00:00:00

  • Association of Long-Term Dynamics in Circulating Testosterone with Serum PSA in Prostate Cancer-Free Men with Initial-PSA

    abstract::We previously reported that an accelerated decline in circulating testosterone level is associated with a higher risk of prostate cancer (PCa). This study is to examine whether testosterone change rate is related to serum prostate-specific antigen (PSA) concentration among PCa-free men. Longitudinal data were derived ...

    journal_title:Hormones & cancer

    pub_type: 杂志文章

    doi:10.1007/s12672-019-00369-y

    authors: Wang K,Chen X,Cheng TD,Qiu P,Bird VY,Prosperi M

    更新日期:2019-12-01 00:00:00

  • Downregulation of miR-196-5p Induced by Hypoxia Drives Tumorigenesis and Metastasis in Hepatocellular Carcinoma.

    abstract::In hepatocellular carcinoma (HCC), the hypoxic tumor microenvironment can drive enhance tumor malignancy and recurrence. The microRNA (miRNA) miR-196-5p has been shown to modulate the progression of several cancer types, but its roles in HCC remain uncertain. In the present report we observed significant miR-196-5p do...

    journal_title:Hormones & cancer

    pub_type: 杂志文章

    doi:10.1007/s12672-019-00370-5

    authors: Zheng H,Bi FR,Yang Y,Hong YG,Ni JS,Ma L,Liu MH,Hao LQ,Zhou WP,Song LH,Yan HL

    更新日期:2019-12-01 00:00:00

  • The Importance of CYP19A1 in Estrogen Receptor-Positive Cholangiocarcinoma.

    abstract::CYP19A1, also called aromatase, is a key enzyme for converting androgens to estrogens of estrogen synthesis. Elevated serum estrogen and high expression levels of estrogen-related proteins are found in cholangiocarcinoma (CCA; bile duct cancer). However, the expression of CYP19A1 in relation to estrogen-related protei...

    journal_title:Hormones & cancer

    pub_type: 杂志文章

    doi:10.1007/s12672-018-0349-2

    authors: Kaewlert W,Sakonsinsiri C,Namwat N,Sawanyawisuth K,Ungarreevittaya P,Khuntikeo N,Armartmuntree N,Thanan R

    更新日期:2018-12-01 00:00:00

  • Germline and somatic mutations in cyclin-dependent kinase inhibitor genes CDKN1A, CDKN2B, and CDKN2C in sporadic parathyroid adenomas.

    abstract::The molecular pathogenesis of sporadic parathyroid adenomas is incompletely understood. The possible role of cyclin-dependent kinase inhibitor (CDKI) genes was raised by recognition of cyclin D1 as a parathyroid oncogene, identification of rare germline mutations in CDKI genes in patients with multiple endocrine neopl...

    journal_title:Hormones & cancer

    pub_type: 杂志文章

    doi:10.1007/s12672-013-0147-9

    authors: Costa-Guda J,Soong CP,Parekh VI,Agarwal SK,Arnold A

    更新日期:2013-10-01 00:00:00

  • Silent corticogonadotroph adenomas: clinical and cellular characteristics and long-term outcomes.

    abstract::Silent corticotrophins adenomas (SCAs) are clinically silent and non-secreting but immunostain positively for ACTH. We hypothesize that SCAs comprise both corticotroph and gonadotroph characteristics. Cohort analysis from 1994-2008 with follow-up time ranging from 1-15 years in a tertiary referral center. We compared ...

    journal_title:Hormones & cancer

    pub_type: 杂志文章

    doi:10.1007/s12672-010-0014-x

    authors: Cooper O,Ben-Shlomo A,Bonert V,Bannykh S,Mirocha J,Melmed S

    更新日期:2010-04-01 00:00:00

  • Progesterone and estradiol synergistically promote the lung metastasis of tuberin-deficient cells in a preclinical model of lymphangioleiomyomatosis.

    abstract::Lymphangioleiomyomatosis (LAM) is a female-predominant lung disease that can lead to respiratory failure. LAM cells typically have inactivating tuberous sclerosis 2 (TSC2) mutations, leading to mTORC1 hyperactivation. The gender specificity of LAM suggests that female hormones contribute to disease progression. Clinic...

    journal_title:Hormones & cancer

    pub_type: 杂志文章

    doi:10.1007/s12672-014-0192-z

    authors: Sun Y,Zhang E,Lao T,Pereira AM,Li C,Xiong L,Morrison T,Haley KJ,Zhou X,Yu JJ

    更新日期:2014-10-01 00:00:00

  • BRAF inhibitors: experience in thyroid cancer and general review of toxicity.

    abstract::The US Food and Drug Administration-approved BRAF inhibitors, vemurafenib and dabrafenib, have demonstrated superior efficacy in patients with BRAF-mutant melanomas but have limited efficacy in BRAF-mutant colorectal cancer. Little is known at this time regarding BRAF inhibitors in thyroid cancer. Initial reports in p...

    journal_title:Hormones & cancer

    pub_type: 杂志文章,评审

    doi:10.1007/s12672-014-0207-9

    authors: Cabanillas ME,Patel A,Danysh BP,Dadu R,Kopetz S,Falchook G

    更新日期:2015-02-01 00:00:00

  • Ligand-activated peroxisome proliferator-activated receptor β/δ modulates human endometrial cancer cell survival.

    abstract::Endometrial cancer is the fourth most common malignancy among women and is a major cause of morbidity contributing to approximately 8,200 annual deaths in the USA. Despite advances to the understanding of endometrial cancer, novel interventions for the disease are necessary given that many tumors become refractory to ...

    journal_title:Hormones & cancer

    pub_type: 杂志文章

    doi:10.1007/s12672-013-0157-7

    authors: Ma JJ,Monsivais D,Dyson MT,Coon JS,Malpani S,Ono M,Zhao H,Xin H,Pavone ME,Kim JJ,Chakravarti D,Bulun SE

    更新日期:2013-12-01 00:00:00

  • The Androgen Receptor Supports Tumor Progression After the Loss of Ovarian Function in a Preclinical Model of Obesity and Breast Cancer.

    abstract::The androgen receptor (AR) has context-dependent roles in breast cancer growth and progression. Overall, high tumor AR levels predict a favorable patient outcome, but several studies have established a tumor promotional role for AR, particularly in supporting the growth of estrogen receptor positive (ER-positive) brea...

    journal_title:Hormones & cancer

    pub_type: 杂志文章

    doi:10.1007/s12672-017-0302-9

    authors: Wellberg EA,Checkley LA,Giles ED,Johnson SJ,Oljira R,Wahdan-Alaswad R,Foright RM,Dooley G,Edgerton SM,Jindal S,Johnson GC,Richer JK,Kabos P,Thor AD,Schedin P,MacLean PS,Anderson SM

    更新日期:2017-12-01 00:00:00

  • Metformin-induced killing of triple-negative breast cancer cells is mediated by reduction in fatty acid synthase via miRNA-193b.

    abstract::The anti-diabetic drug metformin (1,1-dimethylbiguanide hydrochloride) reduces both the incidence and mortality of several types of cancer. Metformin has been shown to selectively kill cancer stem cells, and triple-negative breast cancer (TNBC) cell lines are more sensitive to the effects of metformin as compared to l...

    journal_title:Hormones & cancer

    pub_type: 杂志文章

    doi:10.1007/s12672-014-0188-8

    authors: Wahdan-Alaswad RS,Cochrane DR,Spoelstra NS,Howe EN,Edgerton SM,Anderson SM,Thor AD,Richer JK

    更新日期:2014-12-01 00:00:00

  • The Metabolism, Analysis, and Targeting of Steroid Hormones in Breast and Prostate Cancer.

    abstract::Breast and prostate cancers are malignancies in which steroid hormones drive cellular proliferation. Over the past century, this understanding has led to successful treatment strategies aimed to inhibit hormone-mediated tumor growth. Nonetheless, disease relapse and progression still pose significant clinical problems...

    journal_title:Hormones & cancer

    pub_type: 杂志文章,评审

    doi:10.1007/s12672-016-0259-0

    authors: Capper CP,Rae JM,Auchus RJ

    更新日期:2016-06-01 00:00:00

  • Altered PTEN, ATRX, CHGA, CHGB, and TP53 expression are associated with aggressive VHL-associated pancreatic neuroendocrine tumors.

    abstract::Von Hippel-Lindau (VHL) syndrome is an inherited cancer syndrome in which 8-17 % of germline mutation carriers develop pancreatic neuroendocrine tumors (PNETs). There is limited data on prognostic markers for PNETs other than Ki-67, which is included in the World Health Organization classification system. Recently, sp...

    journal_title:Hormones & cancer

    pub_type: 杂志文章

    doi:10.1007/s12672-013-0134-1

    authors: Weisbrod AB,Zhang L,Jain M,Barak S,Quezado MM,Kebebew E

    更新日期:2013-06-01 00:00:00

  • CUDC-101, a Novel Inhibitor of Full-Length Androgen Receptor (flAR) and Androgen Receptor Variant 7 (AR-V7) Activity: Mechanism of Action and In Vivo Efficacy.

    abstract::Castration-resistant prostate cancer (CRPC) is an androgen receptor (AR)-dependent disease expected to cause the death of more than 27,000 Americans in 2015. There are only a few available treatments for CRPC, making the discovery of new drugs an urgent need. We report that CUDC-101 (an inhibitor od HER2/NEU, EGFR and...

    journal_title:Hormones & cancer

    pub_type: 杂志文章

    doi:10.1007/s12672-016-0257-2

    authors: Sun H,Mediwala SN,Szafran AT,Mancini MA,Marcelli M

    更新日期:2016-06-01 00:00:00

  • Recent Use of Oral Contraceptives and Risk of Luminal B, Triple-Negative, and HER2-Overexpressing Breast Cancer.

    abstract::Oral contraceptive use is a well-established risk factor for breast cancer and is common among reproductive-aged women in the USA. Its relationship with less common, more aggressive, molecular subtypes is less clear. A population-based case-case analysis was conducted comparing three less common molecular subtypes to ...

    journal_title:Hormones & cancer

    pub_type: 杂志文章

    doi:10.1007/s12672-019-00362-5

    authors: Lorona NC,Cook LS,Tang MC,Hill DA,Wiggins CL,Li CI

    更新日期:2019-06-01 00:00:00

  • Suppression of metastatic murine ovarian cancer cells by transduced embryonic progenitor cells.

    abstract::Ovarian cancer is the leading cause of death among gynecological malignancies. Chemotherapy alone is not sufficient to achieve long-term survival of the patient with advanced stage ovarian cancer. Although cancer immune therapy has long been expected as a new modality for ovarian cancer, very few trials have been clin...

    journal_title:Hormones & cancer

    pub_type: 杂志文章

    doi:10.1007/s12672-010-0046-2

    authors: Mandai M,Hamanishi J,Abiko K,Matsumura N,Baba T,Yoshioka Y,Konishi I

    更新日期:2010-12-01 00:00:00

  • Micro-RNA-204 Participates in TMPRSS2/ERG Regulation and Androgen Receptor Reprogramming in Prostate Cancer.

    abstract::Cancer progression is driven by genome instability incurred rearrangements such as transmembrane protease, serine 2 (TMPRSS2)/v-ets erythroblastosis virus E26 oncogene (ERG) that could possibly turn some of the tumor suppressor micro-RNAs into pro-oncogenic ones. Previously, we found dualistic miR-204 effects, acting ...

    journal_title:Hormones & cancer

    pub_type: 杂志文章

    doi:10.1007/s12672-016-0279-9

    authors: Todorova K,Metodiev MV,Metodieva G,Mincheff M,Fernández N,Hayrabedyan S

    更新日期:2017-02-01 00:00:00

  • Risk of Second Primary Female Genital Malignancies in Women with Breast Cancer: a SEER Analysis.

    abstract::Breast cancer survivors are at an increased risk of second primary cancers, and the risk factors for the latter may have clinical significance. The aims of our study were to evaluate the incidences and risk factors of second primary female genital cancers (corpus uteri, cervix uteri plus ovary) in a large cohort of br...

    journal_title:Hormones & cancer

    pub_type: 杂志文章

    doi:10.1007/s12672-018-0330-0

    authors: Li Z,Wu Q,Song J,Zhang Y,Zhu S,Sun S

    更新日期:2018-06-01 00:00:00

  • Dietary fat, fiber, and carbohydrate intake and endogenous hormone levels in premenopausal women.

    abstract::The authors conducted a cross-sectional study to investigate the associations of fat, fiber, and carbohydrate intake with endogenous estrogen, androgen, and insulin-like growth factor (IGF) levels among 595 premenopausal women. Overall, no significant associations were found between dietary intake of these macronutrie...

    journal_title:Hormones & cancer

    pub_type: 杂志文章

    doi:10.1007/s12672-010-0050-6

    authors: Cui X,Rosner B,Willett WC,Hankinson SE

    更新日期:2010-10-01 00:00:00

  • Effects of oestrogen on microRNA expression in hormone-responsive breast cancer cells.

    abstract::Oestrogen receptor alpha (ERα) is a ligand-dependent transcription factor that mediates oestrogen effects in hormone-responsive cells. Following oestrogenic activation, ERα directly regulates the transcription of target genes via DNA binding. MicroRNAs (miRNAs) represent a class of small noncoding RNAs that function a...

    journal_title:Hormones & cancer

    pub_type: 杂志文章

    doi:10.1007/s12672-012-0102-1

    authors: Ferraro L,Ravo M,Nassa G,Tarallo R,De Filippo MR,Giurato G,Cirillo F,Stellato C,Silvestro S,Cantarella C,Rizzo F,Cimino D,Friard O,Biglia N,De Bortoli M,Cicatiello L,Nola E,Weisz A

    更新日期:2012-06-01 00:00:00

  • Thyroid Hormone Promotes β-Catenin Activation and Cell Proliferation in Colorectal Cancer.

    abstract::Thyroid hormone status has long been implicated in cancer development. Here we investigated the role of thyroxine (T4) in colorectal cancer cell lines HCT 116 (APC wild type) and HT-29 (APC mutant), as well as the primary cultures of cancer cells derived from patients. Cell proliferation was evaluated with standard as...

    journal_title:Hormones & cancer

    pub_type: 杂志文章

    doi:10.1007/s12672-018-0324-y

    authors: Lee YS,Chin YT,Shih YJ,Nana AW,Chen YR,Wu HC,Yang YSH,Lin HY,Davis PJ

    更新日期:2018-06-01 00:00:00

  • Estrogen Signaling in Endometrial Cancer: a Key Oncogenic Pathway with Several Open Questions.

    abstract::Endometrial cancer is the most common gynecological cancer in the developed world, and it is one of the few cancer types that is becoming more prevalent and leading to more deaths in the USA each year. The majority of endometrial tumors are considered to be hormonally driven, where estrogen signaling through estrogen ...

    journal_title:Hormones & cancer

    pub_type: 杂志文章,评审

    doi:10.1007/s12672-019-0358-9

    authors: Rodriguez AC,Blanchard Z,Maurer KA,Gertz J

    更新日期:2019-06-01 00:00:00

  • Trends in distant-stage breast, colorectal, and prostate cancer incidence rates from 1992 to 2004: potential influences of screening and hormonal factors.

    abstract::Differential utilization of cancer screening between populations could lead to changes in cancer disparities. Evaluating incidence rates trends is one means of monitoring these disparities. Using Surveillance, Epidemiology, and End Results data, we compared annual percent changes (APC) in age-adjusted incidence rates ...

    journal_title:Hormones & cancer

    pub_type: 杂志文章

    doi:10.1007/s12672-009-0002-1

    authors: McDougall JA,Li CI

    更新日期:2010-02-01 00:00:00

  • The Two Faces of Adjuvant Glucocorticoid Treatment in Ovarian Cancer.

    abstract::Adjuvant glucocorticoid treatment is routinely used in the treatment of ovarian cancer to mitigate the undesirable side effects of chemotherapy, thereby enhancing tolerability to higher cytotoxic drug doses and frequency of treatment cycles. However, in vitro and preclinical in vivo and ex vivo studies indicate that g...

    journal_title:Hormones & cancer

    pub_type: 杂志文章,评审

    doi:10.1007/s12672-017-0319-0

    authors: Djedovic V,Lee YY,Kollara A,May T,Brown TJ

    更新日期:2018-04-01 00:00:00

  • BUB1 immunolocalization in breast carcinoma: its nuclear localization as a potent prognostic factor of the patients.

    abstract::Mitotic checkpoint is a fundamental mechanism involved in fidelity mitotic chromosome segregation, and its alteration results in progression of human malignancies. In this study, we examined expression profiles of seven mitotic checkpoint genes in 20 breast carcinomas using microarray analysis. Results demonstrated th...

    journal_title:Hormones & cancer

    pub_type: 杂志文章

    doi:10.1007/s12672-012-0130-x

    authors: Takagi K,Miki Y,Shibahara Y,Nakamura Y,Ebata A,Watanabe M,Ishida T,Sasano H,Suzuki T

    更新日期:2013-04-01 00:00:00